May 2011 Briefing - Otolaryngology

Here are what the editors at HealthDay consider to be the most important developments in Otolaryngology for May 2011. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.

Effect Estimates May Be Inflated in Biomarker Studies

TUESDAY, May 31 (HealthDay News) -- Biomarker effects are often overestimated in highly cited studies compared to the effects reported in subsequent meta-analyses of the same associations, according to a review published in the June 1 issue of the Journal of the American Medical Association.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Contact With Drug Industry Linked to Positive Attitudes

WEDNESDAY, May 25 (HealthDay News) -- The extent of contact that medical students have with the pharmaceutical industry is associated with positive attitudes about marketing, according to a review published online May 24 in PLoS Medicine.

Abstract
Full Text

Intratympanic Steroids Effectively Treat Hearing Loss

TUESDAY, May 24 (HealthDay News) -- Intratympanic corticosteroids are as effective as oral steroids for the treatment of sudden sensorineural hearing loss, according to a study published in the May 25 issue of the Journal of the American Medical Association.

Abstract
Full Text
Editorial (subscription or payment may be required)

Inappropriate Antibiotic Prescribing Common in Asthma

MONDAY, May 23 (HealthDay News) -- Inappropriate antibiotic prescribing appears to be relatively common among children with asthma, according to two studies published online May 23 in Pediatrics.

Abstract - Paul
Full Text (subscription or payment may be required)
Abstract - De Boeck
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

FDA: SimplyThick Should Not Be Used in Premature Infants

MONDAY, May 23 (HealthDay News) -- The U.S. Food and Drug Administration has notified parents, caregivers, and health care providers not to administer SimplyThick to infants born prior to 37 weeks, as the product may cause necrotizing enterocolitis (NEC), a life-threatening gastrointestinal condition.

More Information

CDC: Swimmer's Ear Results in Over Two Million Visits Yearly

FRIDAY, May 20 (HealthDay News) -- Acute otitis externa (AOE), also known as swimmer's ear, is associated with a large number of doctor visits and substantial medical costs annually, according a report in the May 20 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.

Full Text

Many Medical Students Lack Confidence in Medical Law

FRIDAY, May 20 (HealthDay News) -- The majority of medical students lack confidence in their knowledge and skills across many areas of medical law, according to a study published online May 16 in the Journal of Medical Ethics.

Abstract
Full Text (subscription or payment may be required)

Propranolol Effectively Treats Infantile Hemangiomas

WEDNESDAY, May 18 (HealthDay News) -- Propranolol appears to be an effective first-line therapy in the treatment of infantile head and neck hemangiomas, according to research published in the May issue of the Archives of Otolaryngology -- Head & Neck Surgery.

Abstract
Full Text (subscription or payment may be required)

Triamcinolone Ineffective in Eustachian Tube Dysfunction

WEDNESDAY, May 18 (HealthDay News) -- Tympanometric manifestation of eustachian tube dysfunction (ETD) may not be normalized by treatment with intranasal aqueous triamcinolone acetonide (TAA-AQ), according to a study published in the May issue of the Archives of Otolaryngology -- Head & Neck Surgery.

Abstract
Full Text (subscription or payment may be required)

Childhood Eczema, Rhinitis Predict Adult Asthma

FRIDAY, May 13 (HealthDay News) -- Children who have eczema and rhinitis may be more susceptible to atopic asthma in adulthood, according to research published online April 4 in the Journal of Allergy and Clinical Immunology.

Abstract
Full Text (subscription or payment may be required)

Heller's Myotomy Not Superior Treatment for Achalasia

THURSDAY, May 12 (HealthDay News) -- Laparoscopic Heller's myotomy (LHM) appears no more effective than pneumatic dilation for treatment of achalasia, according to research published in the May 12 issue of the New England Journal of Medicine.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Medical Education Participants Recognize Funding Bias

WEDNESDAY, May 11 (HealthDay News) -- Although most medical professionals believe that commercial funding of continuing medical education (CME) introduces bias, most are not willing to pay higher fees to offset or eliminate such funding sources, according to a study published in the May 9 issue of the Archives of Internal Medicine.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Adding Omalizumab May Improve Uncontrolled Asthma

FRIDAY, May 6 (HealthDay News) -- Omalizumab appears to provide additional clinical benefits in patients with severe allergic asthma that is inadequately controlled with inhaled corticosteroids (ICS) and long-acting beta2-agonists (LABAs), according to a study published in the May 3 issue of the Annals of Internal Medicine.

Abstract
Full Text (subscription or payment may be required)

Obstructive Sleep Apnea Better After Adenotonsillectomy

THURSDAY, May 5 (HealthDay News) -- In children with obstructive sleep apnea syndrome (OSAS), sleep-disordered breathing improves after adenotonsillectomy possibly due to decreases in the sympathetic activity of the autonomic nervous system, according to a study published in the May issue of Chest.

Abstract
Full Text (subscription or payment may be required)

Leukotriene-Receptor Antagonists Effective in Asthma

WEDNESDAY, May 4 (HealthDay News) -- Use of a leukotriene-receptor antagonist (LTRA) may be as effective as an inhaled glucocorticoid as first-line controller therapy, and as effective as a long-acting beta2-agonist (LABA) as an add-on therapy, for the treatment of asthma patients, according to the findings of two pragmatic trials published in the May 5 issue of the New England Journal of Medicine.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

CDC: Asthma Prevalence on the Rise in United States

TUESDAY, May 3 (HealthDay News) -- The prevalence of asthma among both adults and children has increased in the last decade, and asthma costs have increased in recent years as well, according to a report in the May 3 early-release issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.

Full Text

Related Stories

No stories found.
logo
www.healthday.com